GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected.
GWPH shares gained 19% during market hours. The stock has increased 4% since the beginning of this year.
Epidiolex accounted for a lion’s share of the total revenues, contributing $132.6 million in Q3.
CEO Justin Gover said, “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”
____
Most Popular
KBH Earnings: KB Home Q1 profit drops on lower sales, misses estimates
Homebuilder KB Home (NYSE: KBH) on Monday announced financial results for the first quarter of 2025, reporting lower revenues and profit. The bottom line fell short of expectations. First-quarter net
Can Nike (NKE) achieve sustainable growth under new leadership?
Nike, Inc. (NYSE: NKE) is banking on innovations in its product portfolio and improvements in the operating environment to regain strength, while it continues to grapple with multiple headwinds affecting
Here’s how Lennar (LEN) is navigating a challenging macroeconomic environment
Shares of Lennar Corporation (NYSE: LEN) gained over 1% on Monday. The stock has dropped 11% over the past three months. The homebuilder grew its revenues in the first quarter
